G Protein-Coupled Receptor 119 (GPR119) Agonists for the Treatment of Diabetes: Recent Progress and Prevailing Challenges

In this Perspective, recent advances and challenges in the development of GPR119 agonists as new oral antidiabetic drugs will be discussed. Such agonists are expected to exhibit a low risk to induce hypoglycemia as well as to have a beneficial impact on body weight. Many pharmaceutical companies hav...

Full description

Saved in:
Bibliographic Details
Published in:Journal of medicinal chemistry 2016-04, Vol.59 (8), p.3579-3592
Main Authors: Ritter, Kurt, Buning, Christian, Halland, Nis, Pöverlein, Christoph, Schwink, Lothar
Format: Article
Language:English
Subjects:
Clinical Trials as Topic
Diabetes Mellitus - drug therapy
Humans
Ligands
Receptors, G-Protein-Coupled - agonists
Receptors, G-Protein-Coupled - metabolism
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:In this Perspective, recent advances and challenges in the development of GPR119 agonists as new oral antidiabetic drugs will be discussed. Such agonists are expected to exhibit a low risk to induce hypoglycemia as well as to have a beneficial impact on body weight. Many pharmaceutical companies have been active in the search for GPR119 agonists, making it a highly competitive area in the industrial environment. Several GPR119 agonists have been entered into clinical studies, but many have failed either in phase I or II and none has progressed beyond phase II. Herein we describe the strategies chosen by the different medicinal chemistry teams in academia and the pharmaceutical industry to improve potency, physicochemical properties, pharmacokinetics, and the safety profile of GPR119 agonists in the discovery phase in order to improve the odds for successful development.
ISSN:0022-2623
1520-4804
DOI:10.1021/acs.jmedchem.5b01198